Thursday, April 25, 2019
Zymeworks and Daiichi Sankyo move forward with Bispecifics collaboration
And in another vote of confidence for the bispecific mAb market, Daiichi Sankyo has decided to exercise its option with Zymeworks Azymetric technology.
This isn't an ADC yet, but that could change quickly as I'm sure that Zymeworks would be happy to expand its ZLA platform as well.
As the bispecific market continues to heat up, look for more of these types of deals. Daiichi Sankyo knows how to develop targets, and Zymeworks can build the bispecific mAbs.
Are we getting closer to the tipping point? I know I've asked in the past, but each article gets a little closer.